INVIVYD PRESENTS VMS063, A POTENTIAL BEST-IN-CLASS MONOCLONAL ANTIBODY CANDIDATE FOR THE TREATMENT AND PREVENTION OF MEASLES, AT IDWEEK 2026

Reuters · 1d ago

Please log in to view news